For plaintiff firms, “GLP-1 litigation” no longer describes a single federal litigation track. Cases involving GLP-1 medications are now proceeding through two separate multidistrict litigations in the Eastern District of Pennsylvania. MDL 3094 addresses alleged...
GLP-1 medications have become one of the most visible drug categories in the country, and the public conversation around side effects has grown just as quickly. Patients are posting about nausea, vomiting, constipation, gallbladder issues, delayed gastric emptying,...
A Legal Outlook for Law Firms, Trial Lawyers, and Mass Tort Counsel The rapid rise of GLP-1 receptor agonist drugs, including Ozempic®, Wegovy®, Rybelsus® (semaglutide), and Mounjaro® (tirzepatide), has reshaped both the diabetes and weight-loss markets. Alongside...
